Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOAT1 | P35610 | 2/20 | 0.65 |
| ▸ | MEN1 | O00255 | 2/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.65 |
| ▸ | FAAH | O00519 | 1/20 | 0.65 |
| ▸ | TP53 | P04637 | 1/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | CES2 | O00748 | 3/20 | 0.56 |
| ▸ | CES1 | P23141 | 3/20 | 0.56 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.54 |
| ▸ | PPARG | P37231 | 6/20 | 0.54 |
| ▸ | PPARD | Q03181 | 6/20 | 0.54 |
| ▸ | PPARA | Q07869 | 6/20 | 0.54 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.54 |
| ▸ | TSHR | P16473 | 4/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | TLR2 | O60603 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nonanoamide SCHEMBL3840142 | 1.00 | SOAT1 (0.65) | SOAT1MEN1KMT2AFAAHTP53 | |
| Cyclohexane SCHEMBL3840067 | 1.00 | SOAT1 (0.65) | SOAT1MEN1KMT2AFAAHTP53 | |
| Octadecanoic Acid Amide SCHEMBL1407230 | 1.00 | SOAT1 (0.65) | SOAT1MEN1KMT2AFAAHTP53 | |
| Octadecanoic Acid Amide SCHEMBL2896171 | 1.00 | SOAT1 (0.65) | SOAT1MEN1KMT2AFAAHTP53 | |
| Cyclohexane SCHEMBL3839638 | 1.00 | SOAT1 (0.65) | SOAT1MEN1KMT2AFAAHTP53 | |
| Cyclohexane SCHEMBL1714883 | 1.00 | SOAT1 (0.65) | SOAT1MEN1KMT2AFAAHTP53 | |
| Cyclohexane SCHEMBL2898947 | 1.00 | SOAT1 (0.65) | SOAT1MEN1KMT2AFAAHTP53 | |
| Palmitamide SCHEMBL9075014 | 1.00 | SOAT1 (0.65) | SOAT1MEN1KMT2AFAAHTP53 | |
| Cyclohexane SCHEMBL22283339 | 1.00 | SOAT1 (0.65) | SOAT1MEN1KMT2AFAAHTP53 | |
| SCHEMBL8743286 | 0.92 | SOAT1 (0.74) | SOAT1MEN1KMT2AFAAHTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8716279-B2 | Pharmaceutical compositions of clonazepam and method of use thereof | Jazz Pharmaceuticals, Inc. (US) | 2014-05-06 | — | — | US | claimed |
| US-8609651-B2 | Pharmaceutical compositions of benzodiazepines and method of use thereof | Jazz Pharmaceuticals, Inc. (US) | 2013-12-17 | — | — | US | claimed |
| US-20080076761-A1 | Pharmaceutical compositions of clonazepam and method of use thereof | JAZZ PHARMACEUTICALS (US) | 2008-03-27 | — | — | US | claimed |
| US-20080070904-A1 | Pharmaceutical compositions of benzodiazepines and method of use thereof | JAZZ PHARMACEUTICALS (US) | 2008-03-20 | — | — | US | claimed |
| EP-1575617-A1 | USE OF TOPICAL PHARMACEUTICAL COMPOSITIONS COMPRISING AN ACTIVE AGENT AND PERMEATION-ENHANCING BASE FOR THE MANUFACTURE OF A MEDICAMENT TO TREAT VARIOUS FORMS OF INFLAMMATORY DERMATOSIS | Dermatrends, Inc. (US) | 2005-09-21 | — | — | EP | claimed |
| EP-1558228-A1 | TOPICAL ADMINISTRATION OF BASIC ANTIFUNGAL COMPOSITIONS TO TREAT FUNGAL INFECTIONS OF THE NAILS | Dermatrends, Inc. (US) | 2005-08-03 | — | — | EP | claimed |
| EP-1556008-A1 | USE OF BASES FOR THE MANUFACTURE OF A MEDICAMENT IN THE TREATMENT OF DIFFERENT FORMS OF INFLAMMATORY DERMATOSIS | Dermatrends, Inc. (US) | 2005-07-27 | — | — | EP | claimed |
| EP-1429791-A4 | METHOD AND TOPICAL FORMULATION FOR TREATING SKIN CONDITIONS ASSOCIATED WITH AGING | DERMATRENDS INC (US) | 2005-01-05 | — | — | EP | claimed |
| US-6821523-B2 | APPLYING BASIC DRUGS TO SKINS FOR PROPHYLAXIS OF HUMAN PAPILLOMAVIRUS INFECTIONS; SKIN DISODERS | DERMATRENDS, INC. | 2004-11-23 | — | — | US | claimed |
| EP-1429791-A2 | METHOD AND TOPICAL FORMULATION FOR TREATING SKIN CONDITIONS ASSOCIATED WITH AGING | Dermatrends, Inc. (US) | 2004-06-23 | — | — | EP | claimed |
| US-20030059450-A1 | Method and topical formulation for treating skin conditions associated with aging | MAIBACH HOWARD I (US) | 2003-03-27 | — | — | US | claimed |
| EP-0290482-B1 | TRANSDERMAL ABSORPTION DOSAGE UNIT FOR NARCOTIC ANALGESICS AND ANTAGONISTS AND PROCESS FOR ADMINISTRATION | UNIV RUTGERS (US) | 1995-03-08 | — | — | EP | claimed |
| EP-0480996-A1 | BENZOPHENANTHRIDINE ALKALOIDS FOR TOPICAL ACNE TREATMENT | ATRIX LABORATORIES, INC. (US) | 1992-04-22 | — | — | EP | claimed |
| WO-1992000104-A1 | MUCOSAL DELIVERY SYSTEMS FOR TREATMENT OF PERIODONTAL DISEASE | ATRIX LABORATORIES, INC. (US) | 1992-01-09 | — | — | WO | claimed |
| WO-1991000728-A1 | BENZOPHENANTHRIDINE ALKALOIDS FOR TOPICAL ACNE TREATMENT | ATRIX LABORATORIES, INC. (US) | 1991-01-24 | — | — | WO | claimed |
| US-4975271-A | Muscosal delivery systems for treatment of periodontal disease | VIPONT PHARMACEUTICAL, INC. (US) | 1990-12-04 | — | — | US | claimed |
| EP-0290482-A4 | TRANSDERMAL ABSORPTION DOSAGE UNIT FOR NARCOTIC ANALGESICS AND ANTAGONISTS AND PROCESS FOR ADMINISTRATION | — | 1990-11-28 | — | — | EP | claimed |
| US-4806341-A | BACKING LAYER, POLYMER MATRIX DISC WITH DRUG MICRODISPERSED THEREIN | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 1989-02-21 | — | — | US | claimed |
| EP-0290482-A1 | TRANSDERMAL ABSORPTION DOSAGE UNIT FOR NARCOTIC ANALGESICS AND ANTAGONISTS AND PROCESS FOR ADMINISTRATION. | UNIV NEW JERSEY (US) | 1988-11-17 | — | — | EP | claimed |
| WO-1988001497-A1 | TRANSDERMAL ABSORPTION DOSAGE UNIT FOR NARCOTIC ANALGESICS AND ANTAGONISTS AND PROCESS FOR ADMINISTRATION | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 1988-03-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076761-A1 | Pharmaceutical compositions of clonazepam and method of use thereof | GABBR1, GABRA5, GABBR2 | SOAT1 4749/4885MEN1 1645/4885KMT2A 1482/4885 |
| US-20080070904-A1 | Pharmaceutical compositions of benzodiazepines and method of use thereof | GABRA5, GABBR1, GABRA6 | SOAT1 4594/4885MEN1 1365/4885KMT2A 1914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.